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Twenty per cent of sentinel lymph node (SLN)-positive melanoma patients have positive non-SLN lymph nodes in completion lymph
node dissection (CLND). We investigated SLN tumour load, non-sentinel positivity and disease-free survival (DFS) to assess whether
certain patients could be spared CLND. Sentinel lymph node biopsy was performed on 392 patients between 1999 and 2005.
Median observation period was 38.8 months. Sentinel lymph node tumour load did not predict non-SLN positivity: 30.8% of patients
with SLN macrometastases (X2mm) and 16.4% with micrometastases (p2mm) had non-SLN positivity (P¼0.09). Tumour
recurrences after positive SLNs were more than twice as frequent for SLN macrometastases (51.3%) than for micrometastases
(24.6%) (P¼0.005). For patients with SLN micrometastases, the DFS analysis was worse (P¼0.003) when comparing those with
positive non-SLNs (60% recurrences) to those without (17.6% recurrences). This difference did not translate into significant
differences in DFS: patients with SLN micrometastasis, either with (P¼0.022) or without additional positive non-SLNs (Po0.0001),
fared worse than patients with tumour-free SLNs. The 2-mm cutoff for SLN tumour load accurately predicts differences in DFS.
Non-SLN positivity in CLND, however, cannot be predicted. Therefore, contrary to other studies, no recommendations concerning
discontinuation of CLND based on SLN tumour load can be deduced.
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In the past decades, the incidence of cutaneous malignant
melanoma has risen steadily, accompanied by an increase in
mortality in male patients (Mackie et al, 2007). Due to major
prevention efforts, the numbers seem to stabilise in younger age
groups (Mackie et al, 2007). Early diagnosis has increased the
proportion of thin melanomas with a greater likelihood for cure
(McMasters and Swetter, 2003). However, the overall melanoma-
specific survival remains unaffected despite all endeavours towards
improving medical care. Much attention has been focused on the
management of the regional lymph nodes (RLN) in melanoma
patients. In this context, the surgical management strategies of
the RLN have undergone considerable change in the past; with
lymphatic mapping and sentinel lymph node (SLN) identification
being the most relevant contribution (Cabanas, 1977; Wong et al,
1991; Morton et al, 1992). On the basis of the concept that the
regional lymphatics serve as a barrier, temporarily trapping the
orderly tumour spread from the primary site to more distant
locations, it was proposed that the histopathological status of the
SLN would accurately predict melanoma metastases (Reintgen
et al, 1994; Thompson et al, 1995). Today, SNB is the most
important staging tool, because the status of the SLN represents
the most important prognostic factor for recurrence and survival
for melanoma patients and identifies patients who might benefit
from further therapy, such as completion lymph node dissection
(CLND) and adjuvant interferon therapy (Morton et al, 1999; Balch
et al, 2001; Hafner et al, 2004; Eggermont et al, 2007).
Nevertheless, the impact of sentinel lymph node biopsy (SLNB)
on survival remains unclear. Recently, Morton et al (2006)
reported an increased disease-free survival (DFS) with no
significant impact on over-all survival, raising the question
whether lymph node dissection is necessary in case of a positive
SLN. The identification of predictive factors for non-SLN positivity
is a challenge to spare SLN-positive patients the morbidity of
CLND. Unlike the situation for cutaneous melanoma, widely
accepted guidelines exist for breast cancer, which no longer
recommend CLND in patients with an SLN submicrometastasis
(o0.2mm), as they are highly unlikely to recur regionally
(Fournier et al, 2004; Rutgers, 2004). We communicate our SLNB
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sexperience during a 7-year period, particularly focusing on SLN
tumour load, non-SLN positivity and patterns of tumour
recurrence.
PATIENTS AND METHODS
Patients
In all, 392 patients with cutaneous malignant melanoma underwent
SLNB, from the introduction of the method in our institution from
October 1999 to December 2005, and were followed up until 31
September 2006. The median period of observation was 38.8
months.
Technique of SLN identification, wide excision and
sentinel lymph node biopsy
Most patients had already undergone diagnostic excision of the
tumour. All patients underwent WE wide excision of the primary
tumour with a safety margin of 1cm for Breslow thickness below
2mm and a safety margin of 2cm for Breslow thickness above
2mm, in accordance with Swiss guidelines (Dummer et al, 2005).
Neither the triple technique used to identify and remove the SLNs
nor the methodology employed for pathological analysis of the
removed lymph nodes differs from that previously described in the
literature (Hafner et al, 2004; Morton et al, 2005). Consistent with
published guidelines (Cochran et al, 2000), SLNB was recom-
mended for pathological staging of the RLN in patients with a
minimal Breslow of 1.00mm and no clinical or radiological
evidence of melanoma metastasis at the time of diagnosis. SLNB
was equally performed in 15 patients with a smaller tumour
thickness, for whom the referring dermatologist urged staging,
either because the Breslow value was only slightly below 1.00mm
or histological review revealed aggravating factors. Completion
lymph node dissection was recommended for positive SLNs,
according to the Augsburg Consensus guidelines (Cochran et al,
2000). Clinicopathologic characteristics were analysed, including
sex, age, location of the primary tumour, Breslow value and size of
metastatic depots. Disease-free survival and primary recurrences
were determined separately for SLN-positive and SLN-negative
patients according to the anatomic location of the first recurrence.
Local recurrences were defined as satellite recurrence within or up
to 3cm around the wide excision scar; in-transit recurrence was
defined as recurrence in the dermal lymphatics between the site of
the excised primary tumour and the regional nodal basin (RNB).
Recurrences within the staged regional nodal basin were
considered RNB recurrences and distant recurrences as distant
skin, nodal or systemic recurrences beyond the staged RNB. Seven
patients with positive SLNB refused to undergo CLND. They were
counted as SLN-positive and were continued to be followed up at
the Department of Dermatology, but their data were not included
with the CLND group for further analysis.
Follow-up
Patients were all followed up in our outpatient clinic, until
aftercare for all surgical procedures, including the complications
thereof, could safely be terminated. Oncological follow-up was
performed in the Department of Dermatology according to Swiss
national guidelines using a standardised sequence of imaging
techniques (Dummer et al, 2005). Recurrences were registered and
patients treated according to the site of recurrence, surgically,
systemically or by radiotherapy.
Technique of histopathological SLN workup
After 1 day of fixation, the SLN was bisected along the long axis of
the hilar region. If the SLN was thick, the two halves were further
cut into 2-mm thick sections. Depending on its size, the bisected
node was embedded in one or more paraffin blocks. Paraplast
sections at five intervals of 50mm were prepared from each
paraffin block. From each paraplast section, four slides were made
and stained with haematoxylin–eosin and immune stained with
antibodies to S-100, HMB-45 and Pan Melanoma Plus acoording
the EORTC recommendations for working up melanoma SLNs
(Cook et al, 2003). Haematoxylin–eosin- and immune-stained
sections of all samples were reviewed by one experienced
pathologist (DM). There were four different diagnoses based on
the recommendations of the International Union against Cancer:
(i) no tumour, (ii) isolated tumour cells, (iii) micrometastasis
(o2mm) and (iv) macrometastasis (42mm) (Hermanek et al,
1999). As no significant differences between patients with isolated
tumour cells and patients with micrometastasis were found, we
have summarised both groups under the heading of micrometas-
tasis for this analysis, as described in previous studies (Carlson
et al, 2003; Pearlman et al, 2006; Roka et al, 2008).
Statistical analysis
Statistical analysis was performed using SPSS 13. Statistical
comparison between two groups of patients was done using a
t-test for continuous variables and a w
2 test for categorical
variables. Breslow thickness was log-transformed to reach an
approximate normal distribution. Comparison of groups with
respect to the end point ‘time to recurrence’ has been done using
Kaplan–Meier curves and a log-rank test. For the relationship
between a continuous variable (like log Breslow thickness) and
time to recurrence, a Cox regression has been calculated. P-values
below 0.05 were considered as significant.
RESULTS
Patient characteristics and regional lymph node basin
status
Baseline patient characteristics are summarised in Table 1. Male
patients were significantly older at the time of diagnosis
(Po0.0001, t-test). Breslow values for both sexes do not differ
significantly (P¼0.60, t-test). Analysis of the location of the
primary tumour correlated well with gender-specific differences
previously described (Cabanas, 1977), with the lower extremity as
the most common melanoma site in females and the trunk in males
(Po0.0001, w
2 test). A total of 470 hot nodes were identified; on
average 1.2 SLN (range 1–3) were removed per patient. A total of
427 RNBs were staged in our 392 patients; as in 31 patients,
Table 1 Characteristics of 392 patients undergoing SLNB at university
hospital Zurich during 1999–2005
n¼392,
sex
Age
(years)
Breslow
(mm) Primary tumour location
168, female
(42.9%)
48.7 (mean) 2.45 (mean) Head/neck, 20 (11.9%)
49 (median) 1.85 (median) Upper extremity, 41 (24.4%)
16–79 (range) 0.4–17 (range) Trunk, 25 (14.9%)
Unknown n¼4 Lower extremity, 82 (48.8%)
224, male
(57.1%)
57.1 (mean) 2.54 (mean) Head/neck, 31 (13.8%)
61 (median) 1.90 (median) Upper extremity, 60 (26.8%)
18–85 range 0.4–14 (range) Trunk, 95 (42.4%)
Unknown n¼6 Lower extremity, 36 (16.1%)
Unknown, 2 (0.9%)
SLN¼sentinel lymph node.
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had hot nodes in three RNBs simultaneously. We staged 221
axillary RNBs, 146 in the groin and 52 in the head and neck area.
Intercalated nodes (popliteal fossa, cubital fossa, medial bicipital
sulcus, lateral chest wall) were identified in eight patients (2%); in
six (1.5%) of them in conjunction with either additional inguinal
or axillary SLNs. All of these intercalated nodes were tumour-free.
The rate of major complications mandating either additional
surgery or stationary hospital care was 2.3%. A total of 114 positive
SLNs (24.5%) in 107 patients (27.3%) were found. Micrometastatic
tumour deposits were found in 66 of 107 (61.7%) patients with
positive SLNs, whereas macrometastases were found in 41 (38.3%)
patients. Out of 66 patients with micrometastases, 11 presented
isolated tumour cells (10.3%). Table 2 displays a comparison,
stratified by age, sex and Breslow thickness of SLN-positive and
SLN-negative patients. Neither gender was significantly associated
with a higher rate of positive SLNs nor, consequently, with a
gender-dependant significantly worse prognosis (P¼0.84, w
2 test).
No statistically significant differences were evident for median and
mean age in SLN-positive and SLN-negative groups (P¼0.23,
t-test). Both mean and median Breslow thickness were significantly
greater in the SLN-positive group (Po0.0001, t-test). Stratification
of the SLN-positive patients according to Breslow values (Table 3)
revealed increasing rates of SLN positivity proportional to greater
thickness of the primary tumour. Influence of the location of the
primary tumour on SLN positivity was statistically insignificant
(Table 4) (P¼0.38, w
2 test). Completion lymph node dissection
was recommended for all 107 patients with positive SLNs. In all,
100 (93.5%) underwent the procedure, seven (6.5%) refused and
their data were not included for the outcome analysis of the SLN-
positive group.
SLN-positive patients – CLND results
We performed a total of 102 CLNDs on 100 patients, as one patient
had bilateral axillary CLNDs and one patient had bilateral groin
CLNDs simultaneously. In all, 46.1% of all CLNDs were axillary
(47/102), 42.2% were in the groin (43/102) and 11.8% were neck
dissections (12/102). No additional positive non-SLN was found in
78% (78/100) of the CLNDs, whereas 22% (22/100) had additional
positive nodes. Sentinel lymph node tumour load did not
effectively predict non-SLN positivity in CLND; 30.8% (12/39) of
the CLND patients with a macrometastasis in their sentinel had
further non-SLN positivity. In comparison, 16.4% (10/61) of those
patients with an SLN micrometastasis had a positive CLND
(P¼0.09, w
2 test).
SLN-positive patients – melanoma recurrence
Sixty-five per cent (65/100) of patients, who underwent CLND,
remained disease-free; 35% (35/100) presented a tumour relapse:
median time to recurrence was 12.5 months (range 3–43 months).
Table 2 Characteristics of sentinel-positive vs sentinel-negative patients
Patients¼392 Age (years) Breslow (mm) Sex
285 SLN-neg
(72.7%)
53 (mean) 1.77 (mean) Male, 56.8% (n¼162)
57 (median) 1.80 (median) Female, 43.2% (n¼123)
16–85 (range) (0.4–14)
(unknown n¼9)
107 SLN-pos
(27.3%)
55 (mean) 3.39 (mean) Male, 57.9% (n¼62)
58 (median) 2.21 (median) Female, 42.1% (n¼45)
20–80 (range) (0.82–17)
(unknown n¼1)
SLN¼sentinel lymph node.
Table 3 SLN positivity, type of metastasis and recurrence stratified according to Breslow thickness of primary tumour, for patients subject to CLND
Breslow (mm)
Patient (%)
(n¼385)
Positive
patient (%)
Micrometastasis in
SLN (as % of positive SLN)
Macrometastasis in
SLN (as % of positive SLN)
Recurrence
after CLND (%)
Unknown 2.6 (n¼10) 10 (n¼1) 100 (n¼1) 0 100 (n¼1)
L/i¼1
o1 3.6 (n¼14) 14.3 (n¼2) 100 (n¼2) 0 0
1–2 48.1 (n¼185) 21.6 (n¼40) 60 (n¼24) 40 (n¼16) 27.5 (n¼11)
L/i¼2
n¼6
d¼3
2–4 31.7 (n¼122) 27 (n¼33) 66.7 (n¼22) 33.3 (n¼11) 30.3 (n¼11)
L/i¼5
n¼3
d¼3
44 14.0 (n¼54) 44.4 (n¼24) 54.2 (n¼13) 45.8 (n¼11) 50 (n¼12)
L/i¼1
n¼2
d¼9
CLND¼completion lymph node dissection; d¼distant; L/I¼local/intransit; n¼nodal; SLN¼sentinel lymph node. The seven patients who refused CLND are excluded from
the total number of patients.
Table 4 Sentinel positivity as a function of the location of the primary
tumour
Sex of
positive patients
Location of primary
tumour (%)
Location of primary
tumour in SLN-pos
patients
Female (n¼45) Head/neck, 20 (11.9%) Head/neck, 13.3% (n¼6)
Upper extremity, 41
(24.4%)
Upper extremity, 17.8%
(n¼8)
Trunk, 25 (14.9%) Trunk, 20% (n¼9)
Lower extremity, 82
(48.8%)
Lower extremity, 48.9%
(n¼22)
Male (n¼62) Head/neck, 31 (13.8%) Head/neck, 11.3% (n¼7)
Upper extremity, 60
(26.8%)
Upper extremity, 24.2%
(n¼15)
Trunk, 95 (42.4%) Trunk, 37.1% (n¼23)
Lower extremity,
36 (16.1%)
Lower extremity,
27.4% (n¼17)
SLN¼sentinel lymph node.
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nodal (11/35, 31.4%) and distant (15/35, 42.9%). Patients without
further positive non-SLNs had significantly less recurrent disease
(26.9%, 21/78) compared to those with additional positive non-
SLNs in CLND (14/22, 63.3%) (P¼0.001, log-rank test) (cf. Table 5
and Figure 1A). The effect of tumour load on recurrence was
pronounced; in general, recurrence rates in the SLN-positive and
SLN-negative groups were 35.0 and 10.9% respectively, the
difference being highly significant (Po0.0001, log-rank test) (cf.
Figure 1D). Among the SLN-positive patients, tumour recurrences
after a positive SLNB were more than twice as frequent for SLN
macrometastases (51.3%, 20/39) than for micrometastases (24.6%,
15/61), the difference being significant in a DFS analysis (P¼0.005,
log-rank test) (cf. Figure 1B). Stratified by the size of SLN
metastasis and the number of additional positive non-SLNs in the
CLND, the impact of SLN tumour load becomes even more
evident: 51 of the 78 patients with no further positive lymph node
in the CLND had micrometastatic tumour depots in their SLNs;
nine of them (17.6%) suffered a relapse. This rate was significantly
higher and more than doubled for the 27 patients in whom the
SLN, although remaining the only positive lymph node even
after CLND, harboured a macrometastasis: 12 patients (44.4%)
exhibited tumour recurrences (P¼0.009, log-rank test). Even more
impressive was the correlation between additional positive non-
SLNs in CLND and tumour recurrence: 66.7% (8/12) of all patients
with SLN macrometastases and 60% (6/10) of patients with SLN
micrometastases who had positive non-SLNs in CLND relapsed
during the mean follow-up period of 38.8 months. The influence of
additional positive non-SLNs aggravated tumour recurrence only
by increasing total tumour burden and did not exert more
prognostic influence than SLN tumour burden alone: patients with
SLN macrometastases and positive non-SLNs did not have
significantly more tumour recurrences compared to those with
SLN micrometastases and positive non-SLNs (P¼0.60). Sentinel
lymph node tumour burden did, however, influence recurrence
significantly when analysing micro- and macrometastases
separately: although for patients with SLN macrometastases, the
difference in the development of tumour recurrences did not differ
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Figure 1 Comparison of Kaplan–Meier curves for disease-free survival. (A) Sentinel lymph node-positive patients without (solid line) and with (dashed
line) additional positive non-SLNs, (B) SLN-positive patients with SLN micrometastases (solid line) and SLN macrometastases (dashed line), (C) SLN-
negative patients (solid line), SLN-positive patients with micrometastases without (bold solid line) and with additional positive non-SLNs in CLND (dashed
line), and (D) SLN-negative (solid line) and SLN-positive (dashed line) patients. P-values were calculated using a log-rank test.
Table 5 Number of positive non-SLNs in CLND and associated tumour
recurrence
No. of positive non-SLNs in
CLND
% Patients
(n¼100)
% Recurrence
(n¼34)
07 8 ( n¼78) 26.9 (n¼21)
18 ( n¼8) 75.0 (n¼6)
27 ( n¼7) 57.1 (n¼4)
X37 ( n¼7) 57.1 (n¼4)
CLND¼completion lymph node dissection; SLN¼sentinel lymph node.
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12) or without (recurrence 44.4%, 12/27) additional non-SLNs in
CLND, for patients with SLN micrometastases, the DFS analysis
was significantly worse when comparing those with additional
non-SLNs (60% recurrences, 6/10) to those without (17.6%
recurrences, 9/51) (P¼0.003, log-rank test). This difference did
not, however, correspond to significant differences in DFS: both
patients with SLN micrometastasis either with (P¼0.022, log-rank
test) or without additional positive non-SLNs (Po0.0001, log-rank
test) fared significantly worse than patients with tumour-free SLNs
(cf. Figure 1C).
For Breslow thickness, another indicator for tumour load, there
was also correlation with tumour recurrence; for intermediate
thickness melanomas (Breslow 1–4mm), the rate of recurrence
after positive SLNB remained within similar margins (Table 3). In
27.5% (11/40) of the patients with a primary tumour thickness of
1–2mm, the tumour relapsed, as well as in 33.3% (11/33) of the
patients with a primary Breslow of 2–4mm. The rate of
recurrence, however, increased sharply for positive SLNs asso-
ciated with a primary melanoma thicker than 4mm; every second
(50%, 12/24) recurred after CLND. The percentage of micro- and
macrometastases, however, remained fairly constant and did not
increase proportionally with Breslow thickness (Table 3) (P¼0.23,
t-test).
Negative patients
During the median period of observation of 38.8 months, 89.1%
(254) of the 285 negative patients showed DFS. In all, 10.9% (Van
Akkooi et al, 2006), however, exhibited recurrences, and the SLNB
was therefore considered false-negative (FN). Identical FN rates
were noted for distant (4.2%, 12/31) and nodal primary recurrence.
Local or in-transit relapse was seen in 2.5% (7/31). All of the RNBs,
in which SLNB was performed, yielded similar rates of FN results.
In all, 7.7% (17/221) of all staged axillary RNBs produced FN
results, 6.2% (9/146) were from SLNBs in the groin and 9.6% (5/52)
came from head and neck RNBs. Median time to recurrence for
FN SLNB patients was 23 months; 24 month for primary distant
relapse, 19 for primary nodal failure and 16 for local and in-transit
recurrence.
DISCUSSION
In this single centre retrospective analysis, we reviewed our
experience with SLNB in cutaneous melanoma. Our well-
characterised patient population was treated and followed using
a structured algorithm and compared well with other series
published. Our main objective was to study the correlation
between SLN tumour load and further non-SLN positivity as well
as DFS.
Consistent with our own data (78%), 67–90% of SLN-positive
patients do not have further non-SLNs that contain tumour
deposits in the CLND specimens (Reintgen et al, 1994; Carlson
et al, 2003; Van Akkooi et al, 2006). As a consequence, the majority
of SLN-positive patients undergo unnecessary surgery associated
with considerable morbidity (Guggenheim et al, 2008). Therefore,
several authors have tried to identify patient, tumour and SLN
characteristics predicting further non-SLN positivity to safely
avoid CLND (Carlson et al, 2003; Van Akkooi et al, 2006; Scolyer
et al, 2007). Although CLND has not yet been proven to positively
influence overall melanoma-specific survival, Cascinelli et al
(2006) have recently shown that CLND is necessary to achieve
the best assessment of prognosis of stage IB and II melanoma and
to identify those patients who, having only positive sentinel nodes
and negative non-sentinel nodes, have a good prognosis. Although
previous studies have failed to consistently identify the same
clinicopathological features as indicators for additional non-SLN
positivity upon CLND or for DFS (Scolyer et al, 2007), SLN tumour
load, nevertheless, was uniformly confirmed by all of these studies
as prognosticator for non-SLN positivity and recurrence. Thus, we
focus our analysis on this characteristic.
There is considerable debate as to how to stratify SLN tumour
burden; Satzger et al (2007) found that isolated immuno-
histochemically positive tumour cells are without prognostic
significance and DFS of these patients did not differ from that of
SLN-negative patients, an observation that is supported in a
broader sense by Van Akkooi et al (2006). In their study, no
patient with an SLN tumour load of o0.1mm had additional non-
SLN positivity upon CLND, and 5-year overall survival was 100%.
On the basis of these data, they suggested that such patients
may be considered SLN-negative and should be spared CLND. A
similar observation, albeit with a cutoff o0.2mm, was made by
Govindarajan et al (2007). Both studies did, however, either not
reach statistical significance (Van Akkooi et al, 2006) or the study
population was relatively small (Govindarajan et al, 2007). Yet
another cutoff based on a novel micromorphometric classification,
albeit this time at 1mm above submicroscopic levels, was
proposed by Starz et al (2004). In his studies, patients with
deposits o1mm had survival rates not significantly different from
those of patients with tumour-free SLNs. As these results proved to
be difficult to reproduce, however, all these observations are
contested by other authors (Scheri et al, 2007; Scolyer et al, 2007).
Scheri et al (2007) found that 12% of their patients with isolated
tumour cells had further positive non-SLNs in their CLND
specimens and that their melanoma-specific survival was sig-
nificantly worse than in those patients with negative SLNs.
The failure to predict the necessicity of CLND based on
submicroscopic SLN tumour load is demonstrated by several
studies; Carlson et al (2003) reported that 22.6% of patients with
isolated tumour cells had further positive non-SLNs upon CLND.
Although the numbers are too small to reach significance, our own
data from patients with isolated tumour cells indicate that indeed
submicroscopic cutoffs and micromorphometric classifications
may not contribute much towards clarifying behavioral and
prognostic differences according to SLN tumour burden. Of the
11 patients with isolated tumour cells in our series, only one
(9.1%) had additional positive non-SLNs, but three (27.3%) had
tumour recurrence during follow-up. The cutoff separating
micrometastases from macrometastases at 2mm, as put forth by
Hermanek et al (1999), however, may allow more promising
conclusions. Several authors have used this cutoff in analysing
their study populations. Despite the fact that 6% of the patients
with micrometastases (isolated tumour cells not differentiated) in
their SLNs had a positive CLND, Pearlman et al (2006) found that
their 5-year survival was at 85% essentially the same as that of
patients with a negative SLNB. Carlson et al (2003) have made a
similar observation: even though SLN tumour burden was not
predictive of non-SLN positivity, the 3-year overall survival for
patients with SLN tumour burden p2mm (including isolated
tumour cells) was significantly higher than that for those with SLN
tumour deposits of 42mm (90 vs 57%), irrespective of whether
patients had positive CLNDs or not. Roka et al (2008) were able to
partly confirm this: even though no significant association between
SLN tumour load and non-SLN positivity was found, the rate
of DFS for patients with an SLN tumour burden of 42mm was
significantly worse. Similar observations come from a study by
Ranieri et al (2002), albeit with a cutoff at 3mm. Our own data
confirm these results in part: SLN tumour burden with a cutoff at
2mm was indeed a significant prognosticator for tumour
recurrence (P¼0.005, log-rank test), with the rates of relapse
during the median observation period more than twice as frequent
for SLN macrometastases (51.3%) as for micrometastases (24.6%).
Moreover, even though there was no association between SLN
tumour burden and additional non-SLN positivity, there was a
clear statistical trend (P¼0.09) in our study indicating that
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spatients with higher SLN tumour burden might be associated twice
as likely with non-SLN positivity. This finding confirms a similar
trend demonstrated by Roka et al (2008) that may reach statistical
significance once analysed in larger study populations. The rates
for positive CLNDs were not significantly different for SLN
macrometastases and micrometastases. This is in accordance with
other studies in which reproducible prediction of non-SLN
positivity on the basis of SLN tumour burden remained elusive
(Ranieri et al, 2002; Carlson et al, 2003; Pearlman et al, 2006; Roka
et al, 2008). Additional positive non-SLNs upon CLND are
widely recognised to adversely influence prognosis (Carlson
et al, 2003). In our study, tumour recurrences were significantly
more frequent in patients with additional positive non-SLNs in
CLND than in those who did not have a positive CLND. Although
our study confirms that predicting non-SLN positivity on the
basis of SLN tumour load is unreliable, it demonstrates that SLN
tumour burden has an impact on DFS. Recent experimental
studies using melanoma cell lines in mice have impressively shown
that melanoma cells can switch their transcriptional profile
from an invasive migrating one to a proliferative profile
associated with melanocytic differentiation (Hoek et al, 2008).
We hypothesise that the evaluation of the invasive markers in
melanoma metastases might improve the predictive accuracy of
the SN status.
Today, neither clinicopathological nor histomorphometrical
characteristics reliably and reproducibly predict non-SLN
positivity in CLND. However, in accordance with several other
authors, our study supports the observation that the cutoff at 2mm
for SLN tumour load serves to accurately predict differences in
DFS. In contrast to other studies, however, patients with SLN
tumour burden p2mm did have DFS significantly worse than
those with tumour-free SLNs. Although far from allowing
conclusions, our study illustrates that we do not as of yet
sufficiently understand what constitutes relevant nodal disease.
Even though CLND has not been proven to improve survival,
pending the results of MSLT-II, no clinical recommendations
concerning the discontinuation of CLND based on SLN tumour
load can be deduced.
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